Intelligence · Patent portfolio
Sarepta Therapeutics Patents
Full USPTO pharma patent portfolio for Sarepta Therapeutics — grant dates, expiration, and drug cross-links.
- Patents
- 102
- Expiring ≤24m
- 0
Quick answer
Sarepta Therapeutics has 102 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
-
US 8697858
Antisense antiviral compound and method for treating influenza viral infection
granted -
US 8618270
Oligonucleotide analog and method for treating flavivirus infections
granted -
US 8592386
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
granted -
US 8536147
Antibacterial antisense oligonucleotide and method
granted -
US 8524676
Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
granted -
US 8501704
Immunosuppression compound and treatment method
granted
Frequently asked questions
How many patents does Sarepta Therapeutics have?
102 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Sarepta Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory